These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28070890)

  • 21. Impact of Pulmonary Valve Replacement on Ventricular Arrhythmias in Patients With Tetralogy of Fallot and Implantable Cardioverter-Defibrillator.
    Bessière F; Gardey K; Bouzeman A; Duthoit G; Koutbi L; Labombarda F; Marquié C; Gourraud JB; Mondoly P; Sellal JM; Bordachar P; Hermida A; Anselme F; Asselin A; Audinet C; Bernard Y; Boveda S; Chevalier P; Clerici G; da Costa A; de Guillebon M; Defaye P; Eschalier R; Garcia R; Guenancia C; Guy-Moyat B; Henaine R; Irles D; Iserin L; Jourda F; Ladouceur M; Lagrange P; Laredo M; Mansourati J; Massoulié G; Mathiron A; Maury P; Nguyen C; Ninni S; Perier MC; Pierre B; Sacher F; Walton C; Winum P; Martins R; Pasquié JL; Thambo JB; Jouven X; Combes N; Di Filippo S; Marijon E; Waldmann V
    JACC Clin Electrophysiol; 2021 Oct; 7(10):1285-1293. PubMed ID: 33933408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of SMART Pass filter in patients with ajmaline-induced Brugada syndrome and subcutaneous implantable cardioverter-defibrillator eligibility failure: results from a prospective multicentre study.
    Conte G; Cattaneo F; de Asmundis C; Berne P; Vicentini A; Namdar M; Scalone A; Klersy C; Caputo ML; Demarchi A; Özkartal T; Salghetti F; Casu G; Passarelli I; Mameli S; Shah D; Burri H; De Ferrari G; Brugada P; Auricchio A
    Europace; 2022 May; 24(5):845-854. PubMed ID: 34499723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sex Differences in Outcomes of Tetralogy of Fallot Patients With Implantable Cardioverter-Defibrillators.
    Waldmann V; Bouzeman A; Duthoit G; Koutbi L; Bessière F; Labombarda F; Marquié C; Gourraud JB; Mondoly P; Sellal JM; Bordachar P; Hermida A; Al Arnaout A; Anselme F; Audinet C; Bernard Y; Boveda S; Bun SS; Chassignolle M; Clerici G; Da Costa A; de Guillebon M; Defaye P; Elbaz N; Eschalier R; Garcia R; Guenancia C; Guy-Moyat B; Halimi F; Irles D; Iserin L; Jourda F; Ladouceur M; Lagrange P; Laredo M; Mansourati J; Massoulié G; Mathiron A; Maury P; Messali A; Narayanan K; Nguyen C; Ninni S; Perier MC; Pierre B; Pujadas P; Sacher F; Sagnol P; Sharifzadehgan A; Walton C; Winum P; Zakine C; Fauchier L; Martins R; Pasquié JL; Thambo JB; Jouven X; Combes N; Marijon E
    JACC Clin Electrophysiol; 2022 Oct; 8(10):1304-1314. PubMed ID: 36266008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a novel automatic screening tool for determining eligibility for a subcutaneous implantable cardioverter-defibrillator.
    Sakhi R; Yap SC; Michels M; Schinkel AFL; Kauling RM; Roos-Hesselink JW; Theuns DAMJ
    Int J Cardiol; 2018 Dec; 272():97-101. PubMed ID: 30005832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Electrocardiographic Eligibility for Subcutaneous Implantable Cardioverter Defibrillator: Evaluation during Bicycle Exercise.
    Ziacchi M; Corzani A; Diemberger I; Martignani C; Marziali A; Mazzotti A; Massaro G; Rapezzi C; Biffi M; Boriani G
    Heart Lung Circ; 2016 May; 25(5):476-83. PubMed ID: 27044657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The utility of routine clinical 12-lead ECG in assessing eligibility for subcutaneous implantable cardioverter defibrillator.
    Thomas JA; Perez-Alday EA; Hamilton C; Kabir MM; Park EA; Tereshchenko LG
    Comput Biol Med; 2018 Nov; 102():242-250. PubMed ID: 29754992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Follow-Up of Patients With Tetralogy of Fallot and Implantable Cardioverter Defibrillator: The DAI-T4F Nationwide Registry.
    Waldmann V; Bouzeman A; Duthoit G; Koutbi L; Bessiere F; Labombarda F; Marquié C; Gourraud JB; Mondoly P; Sellal JM; Bordachar P; Hermida A; Anselme F; Asselin A; Audinet C; Bernard Y; Boveda S; Bru P; Bun SS; Clerici G; Da Costa A; de Guillebon M; Defaye P; Elbaz N; Eschalier R; Garcia R; Guenancia C; Guy-Moyat B; Halimi F; Irles D; Iserin L; Jourda F; Ladouceur M; Lagrange P; Laredo M; Mansourati J; Massoulié G; Mathiron A; Maury P; Messali A; Narayanan K; Nguyen C; Ninni S; Perier MC; Pierre B; Pujadas P; Sacher F; Sagnol P; Sharifzadehgan A; Walton C; Winum P; Zakine C; Fauchier L; Martins R; Pasquié JL; Thambo JB; Jouven X; Combes N; Marijon E;
    Circulation; 2020 Oct; 142(17):1612-1622. PubMed ID: 32998542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Right versus left parasternal electrode position in the entirely subcutaneous ICD.
    Bettin M; Dechering D; Frommeyer G; Larbig R; Löher A; Reinke F; Köbe J; Eckardt L
    Clin Res Cardiol; 2018 May; 107(5):389-394. PubMed ID: 29285623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can QRS scoring predict left ventricular scar and clinical outcomes?
    Rosengarten JA; Scott PA; Chiu OK; Shambrook JS; Curzen NP; Morgan JM
    Europace; 2013 Jul; 15(7):1034-41. PubMed ID: 23493411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of diurnal variations in the QRS complex and T waves on the eligibility for subcutaneous implantable cardioverter-defibrillators.
    Miwa N; Nagata Y; Yamaguchi T; Nagase M; Sasaki T; Nozato T; Ashikaga T; Goya M; Hirao K
    Heart Rhythm; 2019 Jun; 16(6):913-920. PubMed ID: 30616021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Right Parasternal Electrode Configuration Converts a Failed Electrocardiographic Screening to a Pass for Subcutaneous Implantable Cardioverter-Defibrillator Implantation.
    Chan NY; Yuen HC; Mok NS
    Heart Lung Circ; 2015 Dec; 24(12):e203-5. PubMed ID: 26320627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implantable cardioverter-defibrillator therapy in adult patients with tetralogy of Fallot.
    Witte KK; Pepper CB; Cowan JC; Thomson JD; English KM; Blackburn ME
    Europace; 2008 Aug; 10(8):926-30. PubMed ID: 18442962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eligibility of cardiac resynchronization therapy patients for subcutaneous implantable cardioverter defibrillators.
    Moubarak G; Maison-Blanche P; Thomas O
    J Electrocardiol; 2018; 51(3):531-533. PubMed ID: 29273233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Left ventricular longitudinal function predicts life-threatening ventricular arrhythmia and death in adults with repaired tetralogy of fallot.
    Diller GP; Kempny A; Liodakis E; Alonso-Gonzalez R; Inuzuka R; Uebing A; Orwat S; Dimopoulos K; Swan L; Li W; Gatzoulis MA; Baumgartner H
    Circulation; 2012 May; 125(20):2440-6. PubMed ID: 22496160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effect of pulmonary valve replacement on QRS duration in patients with corrected tetralogy of Fallot.
    Oosterhof T; Vliegen HW; Meijboom FJ; Zwinderman AH; Bouma B; Mulder BJ
    Heart; 2007 Apr; 93(4):506-9. PubMed ID: 17065183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brugada syndrome: Eligibility for subcutaneous implantable cardioverter-defibrillator after exercise stress test.
    von Hafe P; Faria B; Dias G; Cardoso F; Alves MJ; Alves A; Rodrigues B; Ribeiro S; Sanfins V; Lourenço A
    Rev Port Cardiol (Engl Ed); 2021 Jan; 40(1):33-38. PubMed ID: 33436324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Who should receive the subcutaneous implanted defibrillator?: The subcutaneous implantable cardioverter defibrillator (ICD) should be considered in all ICD patients who do not require pacing.
    Poole JE; Gold MR
    Circ Arrhythm Electrophysiol; 2013 Dec; 6(6):1236-44; discussion 1244-5. PubMed ID: 24347599
    [No Abstract]   [Full Text] [Related]  

  • 38. Exercise stress test reveals ineligibility for subcutaneous implantable cardioverter defibrillator in patients with Brugada syndrome.
    Tachibana M; Nishii N; Morita H; Nakagawa K; Watanabe A; Nakamura K; Ito H
    J Cardiovasc Electrophysiol; 2017 Dec; 28(12):1454-1459. PubMed ID: 28800177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of a standard 12-lead electrocardiogram to predict the eligibility for a subcutaneous defibrillator.
    Sakhi R; Theuns DAMJ; Cosgun D; Michels M; Schinkel AFL; Kauling RM; Roos-Hesselink JW; Yap SC
    J Electrocardiol; 2019; 55():123-127. PubMed ID: 31170594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Right Parasternal Lead Placement Increases Eligibility for Subcutaneous Implantable Cardioverter Defibrillator Therapy in Adults With Congenital Heart Disease.
    Okamura H; McLeod CJ; DeSimone CV; Webster TL; Bonnichsen CR; Grogan M; Phillips SD; Connolly HM; Ammash NM; Warnes CA; Friedman PA
    Circ J; 2016 May; 80(6):1328-35. PubMed ID: 27109124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.